Sep 17, 2014 at 13:21 | Source: Moneycontrol.com
Beryl Drugs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2014, inter alia, has not declared any dividend for the year.
Sep 17, 2014 at 11:47 | Source: CNBC-TV18
The size of Glargine is expected to be around USD 3-4 billion globally.
Sep 17, 2014 at 09:58 | Source: Moneycontrol.com
Amoxicillin for oral suspension is the generic equivalent to the reference listed drug product (RLD) of Teva and indicated in the treatment of infections due to susceptible Betalactamase-negative strains of the designated micro-organisms.
Sep 16, 2014 at 18:00 | Source: CNBC-TV18
This is a long-term deal and rings in positives for Lupin in terms of fixed milestone payments and expansions in emerging markets. Besides, they do not need to invest in building up a front-end field force in these emerging markets.
Sep 16, 2014 at 14:23 | Source: Moneycontrol.com
"Zydus Cadila has received tentative approval from the US Food and Drug Administration (US FDA) to market (anti-diabetic drug) Glipizide extended release tablets in the strength of 2.5 mg, 5 mg and 10 mg," said the company in its filing.
Sep 16, 2014 at 12:13 | Source: Moneycontrol.com
Zydus Cadila has received tentative approval from USFDA to market Glipizide extended-release tablets in the strength of 2.5 mg, 5 mg and 10 mg. The drug falls in the anti-diabetic segment.
Sep 16, 2014 at 08:08 | Source: Reuters
The market for copycat biotech drugs, known as biosimilars, is becoming more lucrative as patents expire on older, high-priced antibody drugs that rank among the pharmaceutical industry's biggest sellers.
Sep 15, 2014 at 11:00 | Source: Moneycontrol.com
US-based drug maker Gilead Sciences may join hands with atleast five Indian generic pharmaceutical companies for manufacturing and selling cheaper versions of its new hepatitis C medicines.
Sep 12, 2014 at 13:42 | Source: Moneycontrol.com
Taro has recalled two lots of a key drug on September 2, citing failed content uniformity specifications, according to drug regulator. The drug contributes nearly 5 percent of Taro's sales, analysts say.
Sep 12, 2014 at 12:54 | Source: Moneycontrol.com
During the last earnings call, Strides Arcolab had highlighted that from USD 390 million of receivables from Mylan, it expects contingent holdback (of USD 250 million) to get released in Q2 FY15. With 20 days left for Q2FY15 end, dividend could be a near-term catalyst.